Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Oct 17;6(4):709–728. doi: 10.20517/cdr.2023.62

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023.

© The Author(s) 2023. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

PMC Copyright notice

Cetuximab resistance status of isogenic FaDu cell lines is maintained in CB17 Scid mice. (A-D) Tumor kinetics of CB17 Scid mice inoculated with 1 × 10⁶ cetuximab sensitive FaDu-S cells (A and C) or cetuximab resistant FaDu-R cells (B and D) following treatment with vehicle (PBS, n = 2) or cetuximab low (2.5 mg/kg, n = 3). The green area in each graph represents the treatment period [starting from (A) day 13, (B) day 9 or (C and D) day 18]. Data represent mean ± SD. P-values were determined using a linear mixed model; (E) Representative images of immunohistochemical staining for Ki67 (proliferation) and F4/80 (macrophages), shown at 100x. *P < 0.05. ns: Non-significant; PBS: phosphate-buffered saline; -R: cetuximab-resistant HNSCC cell line; -S: cetuximab-sensitive HNSCC cell line.